SK Life Science, Inc. Selects Patheon as Development Services

Partner for Several Innovative CNS Product Candidates 
TORONTO, July 8 /CNW/ - Patheon (TSX:PTI), a global provider of drug 
development and manufacturing services to the international pharmaceutical 
industry, is pleased to have been selected by SK Life Science, Inc. (formerly 
known as SK Bio-Pharmaceuticals), the US-based subsidiary of Korean SK Holdings 
as their development services partner for two additional innovative Central 
Nervous System (CNS) drug candidates. 
"We are very pleased to have been selected by SK Life Science to develop these 
important new drug candidates, and we look forward to continuing to provide 
them with exceptional service on their development projects," said Wes Wheeler, 
President and Chief Executive Officer of Patheon Inc. "This agreement to 
develop SK Life Science's two innovative candidates for the treatment of CNS 
disorders expands upon our existing relationship with the Company, having 
recently completed phase I development and clinical materials manufacturing for 
their next generation pain drug candidate. This agreement also demonstrates our 
continued commitment to provide best in class development and manufacturing 
services to an expanding global customer base, including the growing Korean 
pharmaceutical industry." 
"Patheon produced quality clinical materials for the pain drug project within 
our timelines. As a result we were very comfortable with awarding Patheon these 
two additional key projects," said Dr. S. James Lee, Vice President 
Pharmaceutical Development of SK Life Science. 
Patheon will provide formulation and analytical development services as well as 
clinical supplies for one of the CNS candidates in multiple dosage forms for SK 
Life Science's advanced clinical studies. In addition, Patheon will provide 
development and clinical materials manufacturing services for another CNS 
candidate in Phase I clinical trials. Both of these candidates are being 
developed for one of the largest pharmaceutical therapeutic categories. The 
global CNS market is expected to grow to $63.9 billion by 2010, according to 
Urch Publishing. 
ABOUT SK Life Science, Inc. 
Through its subsidiary SK Life Science, Inc. (http://pharma.sk.com), SK 
Holdings, Co., Ltd., the second largest conglomerate and the leading energy and 
chemical company in Korea, has been engaged in the innovative discovery and 
development of novel therapeutic compounds in the field of neuroscience in 
order to treat CNS disorders including epilepsy, depression, anxiety, 
schizophrenia, Parkinson's disease, and other neurodegenerative disorders. In 
addition to the CNS area of research, SK Life Science is working on the 
discovery and development of novel therapeutic compounds for the treatment of 
metabolic diseases. 
ABOUT PATHEON 
Patheon Inc. (TSX:PTI; www.patheon.com) is a leading global provider of 
contract development and manufacturing services to the global pharmaceutical 
industry. Patheon prides itself in providing the highest quality products and 
services to more than 300 of the world's leading pharmaceutical and 
biotechnology companies. Patheon's services range from preclinical development 
through commercial manufacturing of a full array of dosage forms including 
parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative 
technologies including single-use disposables, Liquid-Filled Hard Capsules and 
a variety of modified release technologies. 
Patheon's comprehensive range of fully integrated Pharmaceutical Development 
Services includes pre-formulation, formulation, analytical development, 
clinical manufacturing, scale-up and commercialization. Patheon can take 
customers direct to clinic with global clinical packaging and distribution 
services and Patheon's Quick to Clinic(TM) programs can accelerate early phase 
development project to clinical trials while minimizing the consumption of 
valuable API. 
Patheon's integrated development and manufacturing network of 11 facilities, 
and 6 development centers across North America and Europe, strives to ensure 
that customer products can be launched with confidence anywhere in the world. 
Caution Concerning Forward-Looking Statements 
This news release may contain forward-looking statements which reflect 
management's expectations regarding the Company's future growth of operations, 
performance (both operational and financial) and business prospects and 
opportunities. These statements are made in the context of the risks and 
uncertainties that are outlined in the Company's public documents, which can be 
accessed on our website at www.patheon.com or on SEDAR at www.sedar.com. 
%SEDAR: 00001700E 
For further information: Mr. Wes Wheeler, President & Chief Executive Officer, 
Tel: (905) 812-2112, Email: wes.wheeler@patheon.com; Mr. Terry Novak, President 
of North America, Chief Marketing Officer, Tel: (862) 207-1262, Email: 
terry.novak@patheon.com; Ms. Jean Treadwell, Investor Relations, Tel: (905) 816-8344, Email: jean.treadwell@patheon.com 
CO: Patheon Inc.
ST: Ontario
NI: MTC ORDER
-0- Jul/08/2008 11:00 GMT
 
 
Press spacebar to pause and continue. Press esc to stop.